Antonio Sacco

Dr. Antonio Sacco

ASST Spedali Civili di Brescia, Brescia, Lombardy, Italy

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YKYawara Kawano
Yawara Kawano
OZOksana Zavidij
Oksana Zavidij
JPJihye Park
Jihye Park
MMMichele Moschetta
Michele Moschetta
KKKatsutoshi Kokubun
Katsutoshi Kokubun
IGIrene M. Ghobrial
Irene M. Ghobrial
Despite significant advances in the treatment of multiple myeloma (MM), most patients succumb to disease progression. One of the major immunosuppressive mechanisms that is believed to play a role in myeloma progression is the expansion of regulatory T cells (Tregs). In this study, we demonstrate that myeloma cells drive Treg expansion and activation by secreting type 1 interferon (IFN). Blocking IFN α and β receptor 1 (IFNAR1) on Tregs significantly decreases both myeloma-associated Treg immunosuppressive function and myeloma progression. Using syngeneic transplantable murine myeloma models and bone marrow (BM) aspirates of MM patients, we found that Tregs were expanded and activated in the BM microenvironment at early stages of myeloma development. Selective depletion of Tregs led to a complete remission and prolonged survival in mice injected with myeloma cells. Further analysis of the interaction between myeloma cells and Tregs using gene sequencing and enrichment analysis uncovered a feedback loop, wherein myeloma-cell-secreted type 1 IFN induced proliferation and expansion of Tregs. By using IFNAR1-blocking antibody treatment and IFNAR1-knockout Tregs, we demonstrated a significant decrease in myeloma-associated Treg proliferation, which was associated with longer survival of myeloma-injected mice. Our results thus suggest that blocking type 1 IFN signaling represents a potential strategy to target immunosuppressive Treg function in MM.

15 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
CCCinzia Caprio
Cinzia Caprio
Antonio SaccoAntonio Sacco
Antonio Sacco
VGViviana Giustini
Viviana Giustini
Aldo RoccaroAldo Roccaro
Aldo Roccaro
Multiple myeloma (MM) is a plasma cell dyscrasia characterized by proliferation of clonal plasma cells within the bone marrow. Several advances in defining key processes responsible for MM pathogenesis and disease progression have been made; and dysregulation of epigenetics, including DNA methylation and histone modification, has emerged as a crucial regulator of MM pathogenesis. In the present review article, we will focus on the role of epigenetic modifications within the specific context of MM.

21 July 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Vanessa DesantisVanessa Desantis
Vanessa Desantis
Antonio Giovanni SolimandoAntonio Giovanni Solimando
Antonio Giovanni Solimando
ISIlaria Saltarella
Ilaria Saltarella
Antonio SaccoAntonio Sacco
Antonio Sacco
VGViviana Giustini
Viviana Giustini
Aldo RoccaroAldo Roccaro
Aldo Roccaro
Multiple myeloma (MM) is a hematological malignancy characterised by proliferation of clonal plasma cells (PCs) within the bone marrow (BM). Myelomagenesis is a multi-step process which goes from an asymptomatic phase, defined as monoclonal gammopathy of undetermined significance (MGUS), to a smouldering myeloma (SMM) stage, to a final active MM disease, characterised by hypercalcemia, renal failure, bone lesions anemia, and higher risk of infections. Overall, microRNAs (miRNAs) have shown to significantly impact on MM tumorigenesis, as a result of miRNA-dependent modulation of genes involved in pathways known to be crucial for MM pathogenesis and disease progression. We aim to revise the literature related to the role of miRNAs as potential diagnostic and prognostic biomarkers, thus highlighting their key role as novel players within the field of MM and related premalignant conditions.

2 May 2019 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
CFCinzia Federico
Cinzia Federico
Antonio SaccoAntonio Sacco
Antonio Sacco
ABANGELO BELOTTI
ANGELO BELOTTI
RRRossella Ribolla
Rossella Ribolla
VCValeria Cancelli
Valeria Cancelli
Aldo RoccaroAldo Roccaro
Aldo Roccaro
Multiple myeloma (MM) is a plasma cell dyscrasia characterized by bone marrow infiltration of clonal plasma cells. The recent literature has clearly demonstrated clonal heterogeneity in terms of both the genomic and transcriptomic signature of the tumor. Of note, novel studies have also highlighted the importance of the functional cross-talk between the tumor clone and the surrounding bone marrow milieu, as a relevant player of MM pathogenesis. These findings have certainly enhanced our understanding of the underlying mechanisms supporting MM pathogenesis and disease progression. Within the specific field of small non-coding RNA-research, recent studies have provided evidence for considering microRNAs as a crucial regulator of MM biology and, in this context, circulating microRNAs have been shown to potentially contribute to prognostic stratification of MM patients. The present review will summarize the most recent studies within the specific topic of microRNAs and circulating microRNAs in MM.